Guillain-Barre Syndrome Clinical Trial
OBJECTIVES:
I. Compare the efficacy of plasmapheresis and human immunoglobulin infusion in minimizing
morbidity and augmenting the pace of recovery in children with Guillain-Barre syndrome.
II. Compare the potential risks, in terms of treatment related side effects and adverse
clinical outcome, between these two treatment modalities.
Status | Terminated |
Enrollment | 170 |
Est. completion date | November 2002 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A to 17 Years |
Eligibility |
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Guillain-Barre syndrome (GBS): Progressive weakness of two or more limbs; Absence or reduced tendon reflexes; No atypical symptoms of GBS (e.g., Miller-Fisher variant); No pure sensory neuropathy; No prior history of GBS Disability at least grade 3 according to Guillain-Barre Study Group grading scale (unable to walk 5 meters without assistance); Must not have improvement of one or more disability grades prior to randomization in this study No paresthesias, numbness, or weakness that began more than 14 days before randomization in this study No CNS involvement --Prior/Concurrent Therapy-- Biologic therapy: No prior treatment with plasmapheresis or infusion of human immunoglobulin (IVIg) Endocrine therapy: No concurrent corticosteroids or other immunosuppressants (except for concurrent medical conditions, e.g., asthma) Radiotherapy: Not specified Surgery: Not specified Other: No concurrent mechanical ventilation --Patient Characteristics-- Age: Under 18 but with at least 3 months of independent walking Hematopoietic: Cerebrospinal fluid leukocyte count less than 50/mm3 Hepatic: No liver failure Renal: No kidney failure Neurological: No other major neurologic diseases, other neuromuscular disorders, or cerebral palsy Other: HIV negative; No contraindications to plasmapheresis or IVIg; No severe uncontrolled infection; No known IgA hypersensitivity; No other preexisting disease that would interfere with assessment of disability grades; No other causes of acquired weakness (e.g., poliomyelitis, botulism, or other etiologies); No diabetes; Not pregnant |
Allocation: Randomized, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Emory University |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04053452 -
Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome
|
N/A | |
Recruiting |
NCT02582853 -
sCD163 as a Potential Biomarker in Guillain- Barré Syndrome
|
N/A | |
Completed |
NCT00056810 -
Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine
|
Phase 2 | |
Completed |
NCT05104762 -
IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients
|
Phase 2/Phase 3 | |
Recruiting |
NCT05630313 -
Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil
|
||
Recruiting |
NCT03801135 -
Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation
|
N/A | |
Active, not recruiting |
NCT01655394 -
Change of Nerve Conduction Properties in IVIg Dependent Neuropathies
|
N/A | |
Completed |
NCT04927598 -
Predictors and Prognostic Factors of Gullian Barrie Syndrome Outcome
|
||
Completed |
NCT06334796 -
Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology
|
Early Phase 1 | |
Not yet recruiting |
NCT04092140 -
Neuromuscular Ultrasound in Correlation to Neurophysiological Findings
|
||
Not yet recruiting |
NCT04550611 -
Mini-pool Intravenous Immunoglobulin (MP-IVIG) in Guillain-Barré Syndrome
|
N/A | |
Withdrawn |
NCT03268304 -
Feasibility of Two New Software Modules for the Rehabilitation of Patients With Neuromuscular Upper Limb Impairments
|
||
Not yet recruiting |
NCT05701189 -
Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome
|
Phase 2 | |
Withdrawn |
NCT02459808 -
Gastrointestinal Transit Time in Patients With Guillain-Barré Syndrome
|
N/A | |
Completed |
NCT04752566 -
A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome
|
Phase 3 | |
Completed |
NCT05292690 -
An Assistive Powered Wheelchair: Stage 2 Trial
|
||
Not yet recruiting |
NCT06300359 -
Prognostic Indicators of Gullian-Barre Syndrome
|
||
Completed |
NCT00575653 -
Safety Study of GBS Following Menactra Meningococcal Vaccination
|
N/A | |
Completed |
NCT05491096 -
Effects of Proprioceptive Neuromuscular Training on Sensory and Motor Function in Guillain Barre Syndrome
|
N/A | |
Not yet recruiting |
NCT05114941 -
Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome
|
N/A |